Clinical trials: Insulin Pump Therapy
Diabetes Mellitus
Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy
Type I diabetes (T1DM) is the second most common chronic illness effecting children in the USA. Worldwide, Type I diabetes is increasing in incidence, and its underlying etiology remains elusive.
- Trial name
- ktpump (NCT00574405)
- Testing
- MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®]), CSII (Animas Corporation insulin pump, model IR 1200)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Arkansas Children's Hospital Research Institute
Type 1 Diabetes
Prospective Study of the Impact of Insulin Pump Therapy in Young Children With Type 1 Diabetes
The purpose of the study is to examine glycemic and neuropsychological outcomes in very young children with Type I diabetes who are being started on insulin pumps and to compare their outcomes to children who are not utilizing…
- Trial name
- NCT00727220
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Indiana University
Type 1 Diabetes Mellitus, Cognitive Change
The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System
The objective of this pilot study is (i) to test the use of an Artificial Pancreas (AP) System as a viable therapy treatment for two vulnerable populations: 6 to 10 year-old and adults older ≥65 years old with T1D; (ii) to assess…
- Trial name
- NCT03674281
- Testing
- SAP, CLC
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Virginia
Type 1 Diabetes
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
A single-arm, multi-center, clinical study to assess the safety profile of the Tandem t:slim X2 with Control-IQ system in children with T1D aged 2-6 years old under free living condition
- Trial name
- NCT04084171
- Testing
- Tandem t:slim X2 with Control-IQ Technology + Dexcom G6
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of Virginia
Type 1 Diabetes
Medtronic MiniMed Implantable Insulin Pump
This research is being done to find out whether subjects previously treated with the implantable insulin pump (IIP) therapy, and now taking insulin by injection, will benefit from re-implantation of IIP.
- Trial name
- NCT00298740
- Testing
- Aventis U-400 Insulin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Johns Hopkins University
Type 1 Diabetes Mellitus
Continue Glucose Monitoring Before Insulin Pump
The purpose of the study is to learn more about blood glucose control when people with Type 1 Diabetes switch to an insulin pump.
- Trial name
- NCT02813421
- Testing
- CGM Informed
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Children's Hospital Los Angeles
Diabetes Mellitus, Type 1
Diabetes Assistant (DiAs) Control-to-Range (CTR) Nocturnal Closed-Loop Camp Study
The primary goal is to test the function of the Diabetes Assistant (DiAs) enhanced control-to-range (CTR) controller in a closely monitored diabetes camp setting. The camp setting will allow us to obtain pilot efficacy data.
- Trial name
- NCT01973413
- Testing
- Diabetes Assistant (DiAs), Tandem t:slim Insulin Pump, Dexcom G4 Platinum sensor
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Virginia
Diabetes Mellitus, Insulin-Dependent
Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)
Within 4 weeks after diagnosis of type 1 diabetes, 10 subjects (pubertal males, 12-17 years old) will be randomized to either receive multiple daily injection (MDI) using Lantus insulin, or continuous subcutaneous insulin…
- Trial name
- NCT00357890
- Testing
- Insulin pump therapy, Multiple daily injections using insulin glargine + rapid acting analog
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nemours Children's Clinic
Type 1 Diabetes Mellitus
CloudConnect: Predictive And Retrospective Clinical Decision Support For Chronic Disease Management
This study is to assess an approach of self-management called CloudConnect, evaluating the impact of CloudConnect Reports on patient engagement, adolescent/parent discussion, and clinical outcomes in adolescent Type 1 Diabetes…
- Trial name
- NCT03676465
- Testing
- CloudConnect Report, Will not receive a CloudConnect Report
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- University of Virginia
Type 1 Diabetes
Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy
Primary Outcomes: Average decrease in A1c from baseline to end of Study Phase (52 weeks) for subjects in the "722 Group" is greater than that for subjects in the "Control (MDI) Group".
- Trial name
- STAR3 (NCT00417989)
- Testing
- MiniMed Paradigm REAL-Time System
- Where
- 30 sites in United States, Canada
- Volunteers
- 485 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes Mellitus
The Artificial Pancreas in Very Young Children With T1D
The suggested clinical trial is part of the KidsAP project funded by the European Commission's Horizon 2020 Framework Programme and JDRF.
- Trial name
- KidsAP02 (NCT03784027)
- Testing
- CamAPS FX, Sensor augmented therapy
- Where
- 8 sites in Austria, Germany and 2 more
- Volunteers
- 81 people
- Sponsor
- University of Cambridge
Diabetes Mellitus, Type 1
SWITCH - Sensing With Insulin Pump Therapy to Control HbA1c
The primary objective of this study is to evaluate whether the patients with Type 1 diabetes mellitus in sub-optimal glycemic control can achieve better glycemic control by using the Medtronic MiniMed Paradigm® REAL-Time Pump…
- Trial name
- SWITCH (NCT00598663)
- Testing
- insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System), insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)
- Where
- 8 sites in Austria, Denmark and 5 more
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Diabetes Mellitus, Type 1
Day and Night Closed-loop in Young People With Type 1 Diabetes
The main study objective is to determine whether 24/7 automated closed-loop glucose control combined with low glucose feature will improve glucose control as measured by HbA1c.
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Endocrine System Diseases
- Trial name
- DAN05 (NCT02925299)
- Testing
- FlorenceM (US) and FlorenceX (UK), Insulin pump therapy
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 133 people
- Sponsor
- Jaeb Center for Health Research